Sutro Biopharma Stock Performance
| STRO Stock | USD 14.95 0.03 0.20% |
On a scale of 0 to 100, Sutro Biopharma holds a performance score of 9. The entity has a beta of -0.64, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Sutro Biopharma are expected to decrease at a much lower rate. During the bear market, Sutro Biopharma is likely to outperform the market. Please check Sutro Biopharma's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Sutro Biopharma's existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sutro Biopharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Sutro Biopharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.2 | Five Day Return (7.66) | Year To Date Return 36.41 | Ten Year Return (90.16) | All Time Return (90.16) |
1 | Sutro Biopharma to Release Quarterly Earnings on Wednesday | 11/05/2025 |
2 | Insider Trading | 11/13/2025 |
3 | Why Sutro Biopharma Inc. stock attracts global investors - Swing Trade High Conviction Investment Ideas - newser.com | 11/20/2025 |
4 | Sutro Biopharma Shares Gap Up Whats Next | 12/03/2025 |
5 | Acquisition by Edward Albini of 7875 shares of Sutro Biopharma subject to Rule 16b-3 | 12/10/2025 |
6 | Disposition of 2500 shares by Chung Jane of Sutro Biopharma subject to Rule 16b-3 | 12/12/2025 |
7 | Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/16/2025 |
8 | Sutro Biopharma Transition to STRO-004Driven Clinical Execution Warrants Hold as Long-Term Upside Meets Near-Term Uncertainty - TipRanks | 12/22/2025 |
9 | Acquisition by Chow Gregory K. of 8200 shares of Sutro Biopharma at 10.38 subject to Rule 16b-3 | 12/23/2025 |
10 | Sutro Biopharma Stock Pre-Market Momentum From Analyst EPS Upgrade - Trefis | 12/26/2025 |
11 | Acquisition by Petree Daniel H of 1500 shares of Sutro Biopharma at 10.38 subject to Rule 16b-3 | 12/29/2025 |
12 | Sutro Biopharma, Inc.s Price Is Right But Growth Is Lacking After Shares Rocket 46 | 12/31/2025 |
13 | Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference | 01/07/2026 |
14 | Stock Recap Is Sutro Biopharma Inc a potential multi bagger - Bull Run Weekly Stock Breakout Alerts - baoquankhu1.vn | 01/13/2026 |
15 | Sutro Biopharma Upgraded at Citizens Jmp | 01/23/2026 |
| Begin Period Cash Flow | 70.1 M | |
| Total Cashflows From Investing Activities | 218.5 M |
Sutro Biopharma Relative Risk vs. Return Landscape
If you would invest 1,100 in Sutro Biopharma on November 1, 2025 and sell it today you would earn a total of 461.00 from holding Sutro Biopharma or generate 41.91% return on investment over 90 days. Sutro Biopharma is currently generating 0.7974% in daily expected returns and assumes 6.6424% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Sutro, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sutro Biopharma Target Price Odds to finish over Current Price
The tendency of Sutro Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 14.95 | 90 days | 14.95 | roughly 2.63 |
Based on a normal probability distribution, the odds of Sutro Biopharma to move above the current price in 90 days from now is roughly 2.63 (This Sutro Biopharma probability density function shows the probability of Sutro Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Sutro Biopharma has a beta of -0.64. This usually implies as returns on the benchmark increase, returns on holding Sutro Biopharma are expected to decrease at a much lower rate. During a bear market, however, Sutro Biopharma is likely to outperform the market. Additionally Sutro Biopharma has an alpha of 0.8244, implying that it can generate a 0.82 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Sutro Biopharma Price Density |
| Price |
Predictive Modules for Sutro Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sutro Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sutro Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Sutro Biopharma is not an exception. The market had few large corrections towards the Sutro Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sutro Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sutro Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.82 | |
β | Beta against Dow Jones | -0.64 | |
σ | Overall volatility | 2.24 | |
Ir | Information ratio | 0.11 |
Sutro Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sutro Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sutro Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Sutro Biopharma is way too risky over 90 days horizon | |
| Sutro Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 274.15 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Sutro Biopharma Upgraded at Citizens Jmp |
Sutro Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sutro Stock often depends not only on the future outlook of the current and potential Sutro Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sutro Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.7 M | |
| Cash And Short Term Investments | 316.9 M |
Sutro Biopharma Fundamentals Growth
Sutro Stock prices reflect investors' perceptions of the future prospects and financial health of Sutro Biopharma, and Sutro Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sutro Stock performance.
| Return On Equity | -18.1 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.05) % | ||||
| Operating Margin | (4.01) % | ||||
| Current Valuation | (16.95 M) | ||||
| Shares Outstanding | 85.14 M | ||||
| Price To Earning | 53.08 X | ||||
| Price To Book | 2.11 X | ||||
| Price To Sales | 1.20 X | ||||
| Revenue | 62.04 M | ||||
| Gross Profit | 274.15 M | ||||
| EBITDA | (180.45 M) | ||||
| Net Income | (227.46 M) | ||||
| Cash And Equivalents | 225.64 M | ||||
| Cash Per Share | 4.33 X | ||||
| Total Debt | 23.15 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 7.44 X | ||||
| Book Value Per Share | (1.02) X | ||||
| Cash Flow From Operations | (191.54 M) | ||||
| Earnings Per Share | (2.60) X | ||||
| Market Capitalization | 79.09 M | ||||
| Total Asset | 387.21 M | ||||
| Retained Earnings | (786.87 M) | ||||
| Working Capital | 211.42 M | ||||
About Sutro Biopharma Performance
By examining Sutro Biopharma's fundamental ratios, stakeholders can obtain critical insights into Sutro Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sutro Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.64) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.68) | (0.64) | |
| Return On Equity | (5.86) | (5.57) |
Things to note about Sutro Biopharma performance evaluation
Checking the ongoing alerts about Sutro Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sutro Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sutro Biopharma is way too risky over 90 days horizon | |
| Sutro Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 62.04 M. Net Loss for the year was (227.46 M) with profit before overhead, payroll, taxes, and interest of 274.15 M. | |
| Sutro Biopharma currently holds about 225.64 M in cash with (191.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.33. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Sutro Biopharma Upgraded at Citizens Jmp |
- Analyzing Sutro Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sutro Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Sutro Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sutro Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sutro Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sutro Biopharma's stock. These opinions can provide insight into Sutro Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value—what Sutro Biopharma's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.